micro-community-banner
 
  • Saved
The association of graft-versus-leukemia effect and graft-versus host disease in haploidentical transplantation with post-transplant cyclophosphamide for AML - PubMed

The association of graft-versus-leukemia effect and graft-versus host disease in haploidentical transplantation with post-transplant cyclophosphamide for AML - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/35022535/

The association of graft-versus-host disease (GVHD) and graft-versus-leukemia effect after stem-cell transplantation (SCT) is well established but with limited data in the setting of haploidentical SCT (haploSCT) with post-transplant cyclophosphamide...



Conclusion/Relevance: “The association of graft-versus-host disease (GVHD) and graft-versus-leukemia effect after stem-cell transplantation (SCT) is well established but with limited data in the setting of haploidentical SCT (haploSCT) with post-transplant cyclophosphamide (PTCy) …. GVHD of any type or grade is not associated with lower...

  • Saved
Relapse and Disease-Free Survival in Patients With Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation Using Older Matched Sibling Donors vs Younger Matched Unrelated Donors - PubMed

Relapse and Disease-Free Survival in Patients With Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation Using Older Matched Sibling Donors vs Younger Matched Unrelated Donors - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/35024768/

This cohort study found higher disease-free survival and lower relapse for allo-HCT in myelodysplastic syndrome using younger MUDs compared with older MSDs. The risk of nonrelapse mortality and GVHD was...



Conclusions and relevance: This cohort study found higher disease-free survival and lower relapse for allo-HCT in myelodysplastic syndrome using younger MUDs compared with older MSDs. The risk of nonrelapse mortality and GVHD was lower with older MSDs. These results suggest that the use of younger MUDs should be considered in the donor...

  • Saved
Highlighting the interaction between immunomodulatory properties of mesenchymal stem cells and signaling pathways contribute to Graft Versus Host Disease management

Highlighting the interaction between immunomodulatory properties of mesenchymal stem cells and signaling pathways contribute to Graft Versus Host Disease management

Source : https://www.sciencedirect.com/science/article/abs/pii/S0966327421001647?via=ihub

Allo-HSCT has been used as a therapeutic approach for hematological malignancies. * GVHD could significantly affect the morbidity and mortality of patients after allo-HSCT. * Mesenchymal stem cell (MSCs) mediated...

/>

Conclusion: MSCs could potentially modulate immune responses, prevent GVHD, and improve survival after allo-HSCT. Previous studies have investigated different signaling pathways' contributions to MSCs immunoregulatory ability. Accordingly, targeting signaling pathways components involved in MSCs related GVHD regulation is proven to be...

  • Saved
Hepatic venoocclusive disease/sinusoidal obstruction syndrome with normal portal vein flow mimicking aggravated chronic hepatic GVHD following inotuzumab ozogamicin salvage therapy: a case report of pathologic-radiologic discrepancy - PubMed

Hepatic venoocclusive disease/sinusoidal obstruction syndrome with normal portal vein flow mimicking aggravated chronic hepatic GVHD following inotuzumab ozogamicin salvage therapy: a case report of pathologic-radiologic discrepancy - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/34987745/

1 Department of Hematology, Catholic Hematology Hospital and Leukemia Research Institute, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea. 2 Department of...


Relevance: Here, we describe a BCP-ALL patient treated with INO for isolated extramedullary relapse after allo-HCT.

  • Saved


Conclusion/Relevance: The transplant episode can be divided into a pre-transplantation assessment phase, an early post-transplantation phase (start of conditioning regimen to ∼3-6 months post-transplant), and a late post-transplantation phase (more than ∼3-6 months post-transplant).